Clinical Trials Logo

Clinical Trial Summary

Determine the effects of tyrosine kinase Inhibitors on liver enzymes and electrolytes in relation to hematologic response in patients with chronic phase chronic meyloid leukemia.. Assiut University Hospital insight..


Clinical Trial Description

CML is a myeloproliferative neoplasm with unique biological and clinical features. CML accounts for 15_20% of newly diagnosed cases of leukemias among adults. CML can present in three clinical phases : chronic phase, accelerated phase and blast phase. CML is characterized by prodction of a breakpoint cluster region abelson(BCR-ABL) fusion protein with ABL kinase activity. This is due to reciprocal translocation between chromosome 9 and 22. Imatinib & Nilotinib, an ABL kinase inhibitors, which has revolutionized the CML therapy, are a selective tyrosine kinase inhibitors. The aim of the study is to determine the changes of liver enzymes and electrolytes in relation to hematologic response during treatment period. ;


Study Design


Related Conditions & MeSH terms

  • Leukemia
  • Patients Diagnosed as Chronic Meyloid Leukemia

NCT number NCT04326933
Study type Observational
Source Assiut University
Contact
Status Active, not recruiting
Phase
Start date January 1, 2020
Completion date March 31, 2022